AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Chairman's report (verbal update)

5. Minutes of previous meeting

6. Appraisal 1
   Sunitinib (Sutent®) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults

7. Appraisal 2
   dasatanib (Sprycel®) for the treatment of newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia in the chronic phase

8. Welsh Analytical Prescribing Support Unit Strategic Plan 2011-12

9. All Wales Prescribing Advisory Group update

10. Implementation Of Dose Banding For SACTs (Systemic Anti Cancer Treatments) Across Wales

11. Date of next meeting
   Wednesday, 12th October 2011 at The Angel Hotel, Abergavenny

Enclosure

1/AWMSG/0911

2/AWMSG/0911

3/AWMSG/0911

4/AWMSG/0911

5/AWMSG/0911

6/AWMSG/0911